Mitsubishi UFJ Trust & Banking Corp Acquires 30,407 Shares of Zoetis Inc. (NYSE:ZTS)

Mitsubishi UFJ Trust & Banking Corp grew its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,801 shares of the company's stock after acquiring an additional 30,407 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.06% of Zoetis worth $46,077,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ZTS. Mission Wealth Management LP raised its holdings in Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares in the last quarter. Hancock Whitney Corp raised its stake in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. VeraBank N.A. lifted its holdings in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC boosted its position in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares during the period. Finally, Procyon Advisors LLC grew its holdings in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of brokerages have recently weighed in on ZTS. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. Finally, Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $215.90.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 over the last ninety days. Corporate insiders own 0.16% of the company's stock.

Zoetis Stock Performance

ZTS traded down $1.99 during trading on Friday, reaching $163.03. 1,550,283 shares of the company's stock were exchanged, compared to its average volume of 2,595,079. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The company has a market capitalization of $73.00 billion, a P/E ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a 50 day moving average price of $166.40 and a 200 day moving average price of $174.55.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.